Sign up for MarketBeat All Access to gain access to MarketBeat’s full suite of research tools:
Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Get Rating) – Investment analysts at Wedbush issued their Q3 2023 earnings per share estimates for Xenon Pharmaceuticals in a report issued on Wednesday, May 11th. Wedbush analyst L. Chico forecasts that the biopharmaceutical company will earn ($0.81) per share for the quarter. Wedbush currently has a “Outperform” rating on the stock. Wedbush also issued estimates for Xenon Pharmaceuticals’ Q4 2023 earnings at ($0.84) EPS, FY2025 earnings at $1.08 EPS and FY2026 earnings at $5.80 EPS.
Several other research analysts have also issued reports on XENE. TheStreet upgraded Xenon Pharmaceuticals from a “d+” rating to a “c” rating in a report on Monday, March 14th. William Blair restated an “outperform” rating on shares of Xenon Pharmaceuticals in a research note on Wednesday, March 2nd. StockNews.com began coverage on shares of Xenon Pharmaceuticals in a research note on Thursday, March 31st. They issued a “sell” rating for the company. Finally, Zacks Investment Research raised shares of Xenon Pharmaceuticals from a “hold” rating to a “buy” rating and set a $33.00 price target on the stock in a research report on Wednesday, May 4th. One investment analyst has rated the stock with a sell rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $41.80.
Shares of NASDAQ:XENE opened at $26.94 on Thursday. The business’s 50 day simple moving average is $30.96 and its two-hundred day simple moving average is $30.18. The firm has a market cap of $1.43 billion, a P/E ratio of -14.48 and a beta of 1.75. Xenon Pharmaceuticals has a 52-week low of $14.65 and a 52-week high of $36.42. Xenon Pharmaceuticals (NASDAQ:XENE – Get Rating) last announced its quarterly earnings results on Tuesday, May 10th. The biopharmaceutical company reported ($0.35) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.38) by $0.03. Xenon Pharmaceuticals had a negative return on equity of 24.14% and a negative net margin of 425.88%. During the same period last year, the company earned ($0.42) EPS.
In other Xenon Pharmaceuticals news, Director Simon N. Pimstone sold 31,086 shares of the stock in a transaction on Monday, March 7th. The stock was sold at an average price of $30.50, for a total transaction of $948,123.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Simon N. Pimstone sold 9,325 shares of the firm’s stock in a transaction on Friday, March 4th. The stock was sold at an average price of $30.61, for a total value of $285,438.25. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 94,974 shares of company stock valued at $2,899,047. 7.48% of the stock is owned by company insiders.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Captrust Financial Advisors purchased a new stake in Xenon Pharmaceuticals during the third quarter valued at about $46,000. Macquarie Group Ltd. lifted its holdings in Xenon Pharmaceuticals by 551.9% during the third quarter. Macquarie Group Ltd. now owns 3,514 shares of the biopharmaceutical company’s stock valued at $54,000 after purchasing an additional 2,975 shares during the last quarter. JPMorgan Chase & Co. lifted its holdings in Xenon Pharmaceuticals by 104.1% during the fourth quarter. JPMorgan Chase & Co. now owns 4,775 shares of the biopharmaceutical company’s stock valued at $149,000 after purchasing an additional 119,961 shares during the last quarter. Morgan Stanley lifted its holdings in Xenon Pharmaceuticals by 101.7% during the first quarter. Morgan Stanley now owns 4,959 shares of the biopharmaceutical company’s stock valued at $89,000 after purchasing an additional 2,500 shares during the last quarter. Finally, ProShare Advisors LLC purchased a new stake in shares of Xenon Pharmaceuticals during the fourth quarter worth $227,000.
Xenon Pharmaceuticals Company Profile (Get Rating)
Xenon Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders.
Recommended Stories
- Get a free copy of the StockNews.com research report on Xenon Pharmaceuticals (XENE)
- Corning Stock is a Technology Value Play
- Anheuser-Busch InBev May Need One More Quarter to Confirm a Buy Signal
- Wolverine Worldwide Is Ready To Rebound
- Wendy’s Growth Story Has Come To An End
- Beyond Meat Could Sizzle After Q1 Results Are Released
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Before you consider Xenon Pharmaceuticals, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Xenon Pharmaceuticals wasn’t on the list.
While Xenon Pharmaceuticals currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
View The 5 Stocks Here
Complete the form below to receive the latest headlines and analysts’ recommendations for your stocks with our free daily email newsletter:
Each market day you’ll get a one-minute market summary to help you invest wisely.
Sign up for MarketBeat All Access to gain access to MarketBeat’s full suite of research tools:
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat’s trending stocks report.
Identify stocks that meet your criteria using seven unique stock screeners. See what’s happening in the market right now with MarketBeat’s real-time news feed. Export data to Excel for your own analysis.
MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.
Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.
Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.
As Featured By:
MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.
Twitter Facebook StockTwits Financial Juice YouTube
© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.
Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds
© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided ‘as-is’ and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.
